Nuvilex Announces Favorable Phase II Clinical Trial Results for Pancreatic Cancer

Nuvilex, Inc. (PINK SHEETS: NVLX) announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

MORE ON THIS TOPIC